Samanwita Khanra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Samanwita Khanra has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Gowthamarajan Kuppusamy
Department of Pharmaceutics, JSS College of Pharmacy, Ooty, Tamilnadu. JSS Academy of Higher Education & Research, Ooty, India
2 shared publicationsNihar Ranjan Bhuyan
Principal, Department of Pharmaceutical Chemistry, Himalayan Pharmacy Institute, Sikkim, Sikkim, India
2 shared publicationsParikshit Roychowdhury
Department of Pharmaceutics, JSS College of Pharmacy, Ooty, Tamilnadu. JSS Academy of Higher Education & Research, Ooty, India
2 shared publications- Akshay Muralidhara
Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, The Nilgiris, India
1 shared publication Imrankhan Nizam
Department of Pharmaceutics, JSS College of Pharmacy, Ooty, Tamil Nadu. JSS Academy of Higher Education & Research, Ooty, India
1 shared publication- Imrankhan Nizam
Department of Pharmaceutics, JSS College of Pharmacy, JSS AHER, Ooty, Nilgiris, Tamil Nadu, India
1 shared publication
Latest Publications
- 12 January 2026
- Published by Bentham Science Publishers Ltd. in Current Cancer Drug Targets
- Vol. 26
Design of Experiments-Based Formulation and Optimization of Oxaliplatin-Loaded Solid Lipid Nanoparticles for the Management of Colorectal Cancer
Introduction: Oxaliplatin is a third-generation platinum-based chemotherapeutic agent widely used for colorectal cancer treatment. However, its therapeutic application is lim-ited by low solubility, systemic toxicity, and poor bioavailability. Methods: Solid lipid nanoparticles (SLNs) were prepared using a micro-emulsion technique and further optimized via Box-Behnken Design (BBD), considering key formulation variables including Glyceryl Monostearate, Soya Lecithin, and Tween 80. Nanoparticles were charac-terized by in vitro drug release, drug loading, encapsulation efficiency, zeta potential, particle size, and polydispersity index (PDI). Cytotoxic efficacy against the HT-29 colorectal cancer cell line was evaluated using the Sulforhodamine B (SRB) assay. Results: The optimized SLN formulation exhibited a mean particle size of 115.41 nm, PDI of 0.202, and zeta potential of +23.1 mV, indicating stability and efficient cellular uptake. Drug loading and encapsulation efficiency were 10.2 ± 0.4% and 92 ± 3.2%, respectively. In vitro release studies showed sustained drug release, reaching 97% over 48 hours. Cytotoxicity as-says demonstrated enhanced efficacy of Oxaliplatin SLNs, with IC₅₀ values of 0.9751 μg/mL at 24 h and 1.168 μg/mL at 48 h, compared to free Oxaliplatin (52.95 μg/mL at 24 h and 16.33 μg/mL at 48 h). Discussion: GMS-based SLNs optimized with Tween 80, lecithin, and DDAB exhibited ideal size, charge, and high encapsulation. FTIR and DSC analyses confirmed component compat-ibility. The formulation showed sustained release and enhanced cytotoxicity, highlighting its potential to improve Oxaliplatin delivery and therapeutic efficacy in colorectal cancer. Conclusion: The optimized Oxaliplatin SLNs demonstrated improved solubility, controlled release, and enhanced cytotoxicity, confirming their promise as a nanocarrier system for col-orectal cancer therapy. Further in vivo studies are required to validate clinical effectiveness.
- 12 January 2026
- Published by Bentham Science Publishers Ltd. in Current Cancer Drug Targets
- Vol. 26
Design of Experiments-Based Formulation and Optimization of Oxaliplatin-Loaded Solid Lipid Nanoparticles for the Management of Colorectal Cancer
Introduction: Oxaliplatin is a third-generation platinum-based chemotherapeutic agent widely used for colorectal cancer treatment. However, its therapeutic application is lim-ited by low solubility, systemic toxicity, and poor bioavailability. Methods: Solid lipid nanoparticles (SLNs) were prepared using a micro-emulsion technique and further optimized via Box-Behnken Design (BBD), considering key formulation variables including Glyceryl Monostearate, Soya Lecithin, and Tween 80. Nanoparticles were charac-terized by in vitro drug release, drug loading, encapsulation efficiency, zeta potential, particle size, and polydispersity index (PDI). Cytotoxic efficacy against the HT-29 colorectal cancer cell line was evaluated using the Sulforhodamine B (SRB) assay. Results: The optimized SLN formulation exhibited a mean particle size of 115.41 nm, PDI of 0.202, and zeta potential of +23.1 mV, indicating stability and efficient cellular uptake. Drug loading and encapsulation efficiency were 10.2 ± 0.4% and 92 ± 3.2%, respectively. In vitro release studies showed sustained drug release, reaching 97% over 48 hours. Cytotoxicity as-says demonstrated enhanced efficacy of Oxaliplatin SLNs, with IC₅₀ values of 0.9751 μg/mL at 24 h and 1.168 μg/mL at 48 h, compared to free Oxaliplatin (52.95 μg/mL at 24 h and 16.33 μg/mL at 48 h). Discussion: GMS-based SLNs optimized with Tween 80, lecithin, and DDAB exhibited ideal size, charge, and high encapsulation. FTIR and DSC analyses confirmed component compat-ibility. The formulation showed sustained release and enhanced cytotoxicity, highlighting its potential to improve Oxaliplatin delivery and therapeutic efficacy in colorectal cancer. Conclusion: The optimized Oxaliplatin SLNs demonstrated improved solubility, controlled release, and enhanced cytotoxicity, confirming their promise as a nanocarrier system for col-orectal cancer therapy. Further in vivo studies are required to validate clinical effectiveness.
- 4 October 2025
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 26 (8) , 1-24
Advances in Pharmaceutical Cocrystals and Nano-Cocrystals: Strategies for Enhancing Solubility and Translating to Clinical Use
Poor oral bioavailability in most modern pharmaceuticals is primarily caused by poor aqueous solubility. Most NCEs (New Chemical Entities) and nearly 40% o
- 4 October 2025
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 26 (8) , 1-24
Advances in Pharmaceutical Cocrystals and Nano-Cocrystals: Strategies for Enhancing Solubility and Translating to Clinical Use
Poor oral bioavailability in most modern pharmaceuticals is primarily caused by poor aqueous solubility. Most NCEs (New Chemical Entities) and nearly 40% o
- 5 September 2024
- Published by Elsevier in Current Pharmaceutical Analysis
- Vol. 20 (8) , 863-873
Development and Validation of an RP-UFLC Method for the Estimation of Oxaliplatin Drug for the Preparation of Oxaliplatin Nanoparticles
Background: Oxaliplatin, a platinum-based antineoplastic agent, is widely used to treat colorectal cancer. It is well-known for its capacity to hinder the development and division of cells, especially fast-dividing ones, like cancer cells, via the creation of DNA adduct. The currently published oxaliplatin analytical methods require a complex, difficult-to-understand procedure, and are costly. Objective: The main objectives of our study were to select the chromatographic parameters, develop a UFLC method and validate it, and validate the results according to ICH guidelines. Methods: In this UFLC study, a normal phase C18 column (250cm x 4.6 mm x5 μm) with a mobile phase containing 0.01 M orthophosphoric acid and acetonitrile (95:5 V/V) has been used at pH 3.5. Flowrate has been fixed at 1ml/min and the sample has been tested in the UV range for detection. The methods have been validated for precision, linearity, forced degradation studies, robustness, and accuracy. Results: The retention time of the drug has been found to be >8min. The calibration curve of the drug has been obtained within the range of 10–240 μg/ml. The results of this analysis have been validated according to ICH guideline Q2 (R1) for registration of human use. Conclusion: The UFLC method we have used for oxaliplatin quantification has been found to be simpler, easier to understand, and more cost-effective than standard HPLC as it has consumed less mobile phase and less time. Thus, we can conclude that this new, simple, and easy method may be a useful alternative to the existing standard methods for oxaliplatin.
- 5 September 2024
- Published by Elsevier in Current Pharmaceutical Analysis
- Vol. 20 (8) , 863-873
Development and Validation of an RP-UFLC Method for the Estimation of Oxaliplatin Drug for the Preparation of Oxaliplatin Nanoparticles
Background: Oxaliplatin, a platinum-based antineoplastic agent, is widely used to treat colorectal cancer. It is well-known for its capacity to hinder the development and division of cells, especially fast-dividing ones, like cancer cells, via the creation of DNA adduct. The currently published oxaliplatin analytical methods require a complex, difficult-to-understand procedure, and are costly. Objective: The main objectives of our study were to select the chromatographic parameters, develop a UFLC method and validate it, and validate the results according to ICH guidelines. Methods: In this UFLC study, a normal phase C18 column (250cm x 4.6 mm x5 μm) with a mobile phase containing 0.01 M orthophosphoric acid and acetonitrile (95:5 V/V) has been used at pH 3.5. Flowrate has been fixed at 1ml/min and the sample has been tested in the UV range for detection. The methods have been validated for precision, linearity, forced degradation studies, robustness, and accuracy. Results: The retention time of the drug has been found to be >8min. The calibration curve of the drug has been obtained within the range of 10–240 μg/ml. The results of this analysis have been validated according to ICH guideline Q2 (R1) for registration of human use. Conclusion: The UFLC method we have used for oxaliplatin quantification has been found to be simpler, easier to understand, and more cost-effective than standard HPLC as it has consumed less mobile phase and less time. Thus, we can conclude that this new, simple, and easy method may be a useful alternative to the existing standard methods for oxaliplatin.